Cardiff Oncology, Inc.
CRDF
$3.97
-$0.185-4.46%
| Weiss Ratings | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.69 | |||
| Price History | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 6.16% | |||
| 30-Day Total Return | 14.93% | |||
| 60-Day Total Return | 21.25% | |||
| 90-Day Total Return | 27.08% | |||
| Year to Date Total Return | -6.92% | |||
| 1-Year Total Return | -26.57% | |||
| 2-Year Total Return | 131.87% | |||
| 3-Year Total Return | 87.91% | |||
| 5-Year Total Return | 296.50% | |||
| 52-Week High % Change | -35.36% | |||
| 52-Week Low % Change | 106.47% | |||
| Price | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $6.42 | |||
| 52-Week Low Price | $2.01 | |||
| 52-Week Low Price (Date) | Aug 05, 2024 | |||
| 52-Week High Price (Date) | Mar 25, 2024 | |||
| Valuation | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 276.08M | |||
| Enterprise Value | 185.85M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.96 | |||
| Earnings Per Share Growth | 3.20% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 329.37 | |||
| Price/Book (Q) | 3.33 | |||
| Enterprise Value/Revenue (TTM) | 271.71 | |||
| Price | $3.97 | |||
| Enterprise Value/EBITDA (TTM) | -3.85 | |||
| Enterprise Value/EBIT | -3.82 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 54.22M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 952 7570 | |||
| Address | 11055 Flintkote Avenue San Diego, CA 92121 | |||
| Website | www.cardiffoncology.com | |||
| Country | United States | |||
| Year Founded | 1999 | |||
| Profitability | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -7,112.71% | |||
| Profit Margin | -6,641.95% | |||
| Management Effectiveness | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -34.01% | |||
| Return on Equity | -- | |||
| Income Statement | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 684.00K | |||
| Total Revenue (TTM) | 684.00K | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | -36.17M | |||
| EBITDA (TTM) | -48.25M | |||
| EBIT (TTM) | -48.65M | |||
| Net Income (TTM) | -45.43M | |||
| Net Income Avl. to Common (TTM) | -45.43M | |||
| Total Revenue Growth (Q YOY) | -3.21% | |||
| Earnings Growth (Q YOY) | -26.24% | |||
| EPS Diluted (TTM) | -0.96 | |||
| EPS Diluted Growth (Q YOY) | -4.02% | |||
| Balance Sheet | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 91.75M | |||
| Cash Per Share (Q) | $1.69 | |||
| Total Current Assets (Q) | 95.05M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 82.95M | |||
| Current Ratio (Q) | 7.079 | |||
| Book Value Per Share (Q) | $1.25 | |||
| Total Assets (Q) | 97.19M | |||
| Total Current Liabilities (Q) | 13.43M | |||
| Total Debt (Q) | 1.52M | |||
| Total Liabilities (Q) | 14.24M | |||
| Total Common Equity (Q) | 82.95M | |||
| Cash Flow | CRDF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 13.73M | |||
| Cash from Financing (TTM) | 53.78M | |||
| Net Change in Cash (TTM) | 29.82M | |||
| Levered Free Cash Flow (TTM) | -23.07M | |||
| Cash from Operations (TTM) | -37.69M | |||
